Table 1 Clinical and epidemiological characteristics of 56 individuals stratified by HCV infection status

No

56

32 (57.1%)

24 (42.9%)

Age (years)

53 (47–59)

55 (47–60)

51 (47–58)

0.289

Sex (male)

27 (48.2%)

16 (50.0%)

11 (45.8%)

0.969

BMI (kg/m²) (n = 34)

25.3 (22.8–28.0)

25.0 (23.2–27.5)

25.3 (22.5–28.4)

0.985

Smoker (n = 22)

–

 Never

–

–

11 (50.0%)

 Previous (> 6 months)

–

–

7 (31.8%)

 Current

–

–

4 (18.2%)

Route of transmission (n = 9)

–

 Intravenous drug user

–

6 (66.7%)

–

 Medical and Aesthetic procedures

–

2 (22.2%)

–

 Work accident

–

1 (11.1%)

–

Time from clearance (years) (n = 23)

–

3.0 (2.0–11.5)

–

–

IFN-λ₄ genotype (rs12979860) (n = 55)

0.802

 CC

32 (58.2%)

19 (61.3%)

13 (54.2%)

 CT

18 (32.7%)

9 (29.0%)

9 (37.5%)

 TT

5 (9.1%)

3 (9.7%)

2 (8.3%)

Stage of liver fibrosis (n = 9)

–

 F0

–

1 (11.1%)

–

 F1

–

7 (77.8%)

–

 F2

–

1 (11.1%)

–

 F3

–

0 (0.0%)

–

 F4

–

0 (0.0%)

–

Liver markers

 FIB4 (n = 46)

1.2 (1.0–1.5)

1.4 (1.2–2.0)

1.0 (0.8–1.2)

0.001

 APRI (n = 48)

0.3 (0.2–0.4)

0.3 (0.3–0.4)

0.2 (0.2–0.3)

0.001

 AST (mg/dL) (n = 54)

21.0 (16.3–29.5)

24.0 (18.5–36.5)

19.0 (15.0–21.0)

0.004

 ALT (mg/dL) (n = 54)

19.5 (15.0–31.8)

25.5 (17.8–34.5)

15.0 (13.0–21.8)

0.011

 GGT (mg/dL) (n = 53)

22.0 (14.0–39.0)

24.0 (16.0–56.0)

21.0 (13.3–30.3)

0.138

Metabolic syndrome markers

 TyG (n = 46)

8.3 (8.1–8.7)

8.4 (8.2–8.7)

8.3 (8.0–8.7)

0.542

 METS IR (n = 32)

33.1 (27.9–41.2)

32.8 (29.2–36.1)

33.4 (27.8–42.2)

0.742